Skip to main content
Erschienen in: Clinical Orthopaedics and Related Research® 7/2016

21.01.2016 | Symposium: Proceedings of the 2015 Musculoskeletal Infection Society

Biofilm Antimicrobial Susceptibility Increases With Antimicrobial Exposure Time

verfasst von: Paulo Castaneda, BSE, Alex McLaren, MD, Gamuchirai Tavaziva, Derek Overstreet, PhD

Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The antimicrobial concentration required to kill all the bacteria in a biofilm, known as the minimum biofilm eradication concentration (MBEC), is typically determined in vitro by exposing the biofilm to serial concentrations of antimicrobials for 24 hours or less. Local delivery is expected to cause high local levels for longer than 24 hours. It is unknown if longer antimicrobial exposures require the same concentration to eradicate bacteria in biofilm. Questions/purposes Does MBEC change with increased antimicrobial exposure time?

Methods

Biofilms were grown for 24 hours using five pathogens (methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and Pseudomonas aeruginosa) and then exposed to four antimicrobials regimens: tobramycin, vancomycin, and tobramycin combined with vancomycin in 3:1 and 1:1 ratios by weight in concentrations of 62.5, 125, 250, 500, 1000, 2000, 4000, and 8000 μg/mL for three durations, 1, 3, and 5 days, in triplicate. MBEC was measured as the lowest concentration that killed all bacteria in the biofilm determined by 21-day subculture.

Results

MBEC was lower when antimicrobial exposure time was longer. For the staphylococcus species, the MBEC was lower when exposure time was 5 days than 1 day in 11 of 12 antimicrobial/microorganism pairs. The MBEC range for these 11 pairs on Day 1 was 4000 to > 8000 μg/mL and on Day 5 was < 250 to 8000 μg/mL. MBEC for tobramycin/P. aeruginosa was 2000 μg/mL on Day 1 and ≤ 250 μg/mL on Day 5, and for E. coli, 125 μg/mL on Day 1 and ≤ 62.5 on Day 5.

Conclusions

Although antimicrobial susceptibility was lower for longer exposure times in the microorganisms we studied, confirmation is required for other pathogens. Clinical Relevance One-day MBEC assays may overestimate the local antimicrobial levels needed to kill organisms in biofilm if local levels are sustained at MBEC or above for longer than 24 hours. Future studies are needed to confirm that antimicrobial levels achieved clinically from local delivery are above the MBEC at relevant time points and to confirm that MBEC for in vitro microorganisms accurately represents MBEC of in vivo organisms in an clinical infection.
Literatur
1.
Zurück zum Zitat Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771–1776.PubMedPubMedCentral Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37:1771–1776.PubMedPubMedCentral
2.
Zurück zum Zitat Cockerill F, Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012. Cockerill F, Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012.
3.
Zurück zum Zitat Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol. 1995;49:711–745.CrossRefPubMed Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol. 1995;49:711–745.CrossRefPubMed
4.
Zurück zum Zitat Dosler S, Mataraci E. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. Peptides. 2013;49:53–58.CrossRefPubMed Dosler S, Mataraci E. In vitro pharmacokinetics of antimicrobial cationic peptides alone and in combination with antibiotics against methicillin resistant Staphylococcus aureus biofilms. Peptides. 2013;49:53–58.CrossRefPubMed
5.
Zurück zum Zitat Evans RC, Holmes CJ. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother. 1987;31:889.CrossRefPubMedPubMedCentral Evans RC, Holmes CJ. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother. 1987;31:889.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Fux C, Wilson S, Stoodley P. Detachment characteristics and oxacillin resistance of Staphyloccocus aureus biofilm emboli in an in vitro catheter infection model. J Bacteriol. 2004;186:4486.CrossRefPubMedPubMedCentral Fux C, Wilson S, Stoodley P. Detachment characteristics and oxacillin resistance of Staphyloccocus aureus biofilm emboli in an in vitro catheter infection model. J Bacteriol. 2004;186:4486.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Girard LP, Ceri H, Gibb AP, Olson M, Sepandj F. MIC Versus MBEC to determine the antibiotic sensitivity of Staphylococcus aureus in peritoneal dialysis peritonitis. Perit Dial Int. 2010;30:652–656.CrossRefPubMed Girard LP, Ceri H, Gibb AP, Olson M, Sepandj F. MIC Versus MBEC to determine the antibiotic sensitivity of Staphylococcus aureus in peritoneal dialysis peritonitis. Perit Dial Int. 2010;30:652–656.CrossRefPubMed
8.
Zurück zum Zitat Kahl BC. Small colony variants (SCVs) of Staphylococcus aureus–a bacterial survival strategy. Infect Genet Evol. 2014;21:515–522.CrossRefPubMed Kahl BC. Small colony variants (SCVs) of Staphylococcus aureus–a bacterial survival strategy. Infect Genet Evol. 2014;21:515–522.CrossRefPubMed
9.
Zurück zum Zitat Kwasny SM, Opperman TJ. Static biofilm cultures of gram-positive pathogens grown in a microtiter format used for anti-biofilm drug discovery. In: Enna SJ, Williams M, Barret JF, Ferkany JW, Kenakin T, Porsolt RD, eds. Current Protocols in Pharmacology. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2010. Kwasny SM, Opperman TJ. Static biofilm cultures of gram-positive pathogens grown in a microtiter format used for anti-biofilm drug discovery. In: Enna SJ, Williams M, Barret JF, Ferkany JW, Kenakin T, Porsolt RD, eds. Current Protocols in Pharmacology. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2010.
10.
Zurück zum Zitat Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5:48–56.CrossRefPubMed Lewis K. Persister cells, dormancy and infectious disease. Nat Rev Microbiol. 2007;5:48–56.CrossRefPubMed
11.
Zurück zum Zitat Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–e55.CrossRefPubMed Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. Clinical Practice Guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–e55.CrossRefPubMed
12.
Zurück zum Zitat McLaren A, Giers MB, Fraser J, Hosack L, Caplan MR, McLemore R. Antimicrobial distribution from local delivery depends on dose: a pilot study with MRI. Clin Orthop Relat Res. 2014;472:3324–3329.CrossRefPubMedPubMedCentral McLaren A, Giers MB, Fraser J, Hosack L, Caplan MR, McLemore R. Antimicrobial distribution from local delivery depends on dose: a pilot study with MRI. Clin Orthop Relat Res. 2014;472:3324–3329.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat McLaren A, Shirtliff M. Biofilms in surgical site infections. In: Hsu W, McLaren A, Springer B, eds. Let’s Discuss Surgical Site Infections. Rosemont, IL, USA: AAOS; 2015. McLaren A, Shirtliff M. Biofilms in surgical site infections. In: Hsu W, McLaren A, Springer B, eds. Let’s Discuss Surgical Site Infections. Rosemont, IL, USA: AAOS; 2015.
15.
Zurück zum Zitat Nelson CL, Hickmon SG, Skinner RA. Treatment of experimental osteomyelitis by surgical debridement and the implantation of bioerodable, polyanhydride-gentamicin beads. J Orthop Res. 1997;15:249–255.CrossRefPubMed Nelson CL, Hickmon SG, Skinner RA. Treatment of experimental osteomyelitis by surgical debridement and the implantation of bioerodable, polyanhydride-gentamicin beads. J Orthop Res. 1997;15:249–255.CrossRefPubMed
16.
Zurück zum Zitat Nishimura S, Tsurumoto T, Yonekura A, Adachi K, Shindo H. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases. J Orthop Sci. 2006;11:46–50.CrossRefPubMed Nishimura S, Tsurumoto T, Yonekura A, Adachi K, Shindo H. Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus epidermidis biofilms isolated from infected total hip arthroplasty cases. J Orthop Sci. 2006;11:46–50.CrossRefPubMed
17.
Zurück zum Zitat Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res. R 2002;66:86–92. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res. R 2002;66:86–92.
18.
19.
Zurück zum Zitat Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656–1660.CrossRefPubMedPubMedCentral Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, Sherertz R, Hachem R. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656–1660.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother. 2009;63:485–488.CrossRefPubMed Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother. 2009;63:485–488.CrossRefPubMed
21.
Zurück zum Zitat Watanakunakorn C, Tisone JC. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1982;22:903.CrossRefPubMedPubMedCentral Watanakunakorn C, Tisone JC. Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1982;22:903.CrossRefPubMedPubMedCentral
Metadaten
Titel
Biofilm Antimicrobial Susceptibility Increases With Antimicrobial Exposure Time
verfasst von
Paulo Castaneda, BSE
Alex McLaren, MD
Gamuchirai Tavaziva
Derek Overstreet, PhD
Publikationsdatum
21.01.2016
Verlag
Springer US
Erschienen in
Clinical Orthopaedics and Related Research® / Ausgabe 7/2016
Print ISSN: 0009-921X
Elektronische ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-016-4700-z

Weitere Artikel der Ausgabe 7/2016

Clinical Orthopaedics and Related Research® 7/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.